Contrast-Enhanced Subharmonic Aided Pressure Estimation (SHAPE) Using Ultrasound Imaging with a Focus on Identifying Portal Hypertension
December 5th, 2020
2.5K views
A protocol for noninvasively estimating ambient pressures utilizing subharmonic ultrasound imaging of infused contrast microbubbles (following appropriate calibration) is described with examples from human patients with chronic liver disease.
Overview
This article presents a noninvasive ultrasound-based technique for accurately measuring internal body pressures using subharmonic signals from microbubble contrast agents. The method, known as Subharmonic Aided Pressure Estimation (SHAPE), is particularly highlighted for diagnosing portal hypertension in the liver, but has broader clinical applications. The protocol details preparation, infusion, imaging, and optimization steps to maximize sensitivity and accuracy of pressure estimation.
Key Study Components
Area of Science
- Medical imaging
- Ultrasound diagnostics
- Noninvasive pressure measurement
Background
- Accurate, noninvasive measurement of internal pressures is a longstanding clinical challenge.
- Ultrasound contrast agents (UCAs) are gas-filled microbubbles that enhance imaging signals.
- Microbubbles exhibit nonlinear oscillations, producing subharmonic signals inversely related to ambient pressure.
- Current imaging techniques cannot provide both relative and absolute pressure estimates noninvasively.
Purpose of Study
- To develop and demonstrate a real-time, noninvasive method for quantifying internal pressures using SHAPE.
- To optimize ultrasound imaging parameters for maximal sensitivity to pressure changes.
- To validate the technique for diagnosing portal hypertension in the liver.
Methods Used
- Preparation and infusion of microbubble-based ultrasound contrast agents.
- Ultrasound imaging using a curvilinear probe and subcostal approach to visualize portal and hepatic veins.
- Activation of subharmonic imaging and amplitude modulation at specific frequencies (2.5 MHz transmit, 1.25 MHz receive).
- Automated SHAPE optimization algorithm to select acoustic output for maximal sensitivity.
- Time-intensity curve analysis and logistic curve fitting to determine optimal imaging parameters.
Main Results
- SHAPE enables real-time, noninvasive quantification of internal pressures with high sensitivity.
- Clear differentiation between patients with and without clinically significant portal hypertension based on subharmonic signals.
- Technique provides both relative and absolute pressure estimates.
- Some anatomical or vascular variations may affect diagnostic accuracy in certain patients.
Conclusions
- SHAPE is a safe, accurate, and noninvasive method for internal pressure measurement.
- It offers unique capabilities not available with other imaging modalities.
- Potential for broad clinical application beyond liver portal hypertension.
Frequently Asked Questions
What is the main advantage of the SHAPE technique?
SHAPE provides noninvasive, real-time, and accurate measurement of internal body pressures, offering both relative and absolute estimates, which is not possible with other imaging methods.
How does the SHAPE technique work?
It uses microbubble ultrasound contrast agents that generate subharmonic signals inversely related to ambient pressure. By optimizing ultrasound parameters, these signals can be used to estimate internal pressures.
What clinical applications does SHAPE have?
While the article focuses on diagnosing portal hypertension in the liver, SHAPE can also be used for monitoring cardiac pressures and treatment of cancers, among other applications.
How is the ultrasound contrast agent prepared and administered?
The agent is reconstituted by adding sterile water, shaken to homogeneity, and infused intravenously using a syringe pump, with careful setup to ensure proper delivery and imaging conditions.
What are the key imaging steps in the SHAPE protocol?
Ultrasound imaging is performed to visualize the portal and hepatic veins, subharmonic imaging is activated, and an automated algorithm optimizes acoustic output for maximal sensitivity to pressure changes.
Are there limitations to the SHAPE technique?
Yes, anatomical or vascular variations in some patients may lead to discrepancies between clinical signs and SHAPE-derived pressure estimates.
Is SHAPE safe for patients?
Yes, the technique is noninvasive and considered safe for clinical use.
Executive Industry Relevance
Noninvasive, quantitative pressure estimation using subharmonic ultrasound imaging with microbubble contrast agents addresses a critical gap in translational research and preclinical model validation. SHAPE enables real-time, reproducible measurement of vascular pressures, supporting mechanistic de-risking and predictive confidence in disease-relevant systems such as portal hypertension. This capability enhances early discovery, target validation, and risk-adjusted portfolio advancement in biopharma R&D.
Strategic Applications in Biopharma R&D
Early Discovery & Target Validation
- Enables direct interrogation of hemodynamic hypotheses in disease models.
- Supports functional target validation by quantifying pressure changes in response to interventions.
- Facilitates mechanistic de-risking by providing quantitative, noninvasive readouts.
- Improves predictive confidence for vascular and hepatic disease targets.
Screening & Assay Development
- Provides standardized, quantitative pressure measurements for assay development.
- Enables reproducible evaluation of compound effects on vascular pressures.
- Supports scalability and platform reuse across multiple preclinical models.
- Delivers reliable, real-time outputs for screening candidate interventions.
Translational & Preclinical Research
- Aligns pressure measurements with disease-relevant biomarkers in preclinical models.
- Ensures continuity from discovery through preclinical validation for vascular indications.
- Supports risk-adjusted advancement decisions based on quantitative endpoints.
- Provides mechanistic insight into intervention effects on portal hypertension.
Pipeline & Workflow Integration
SHAPE integrates into the discovery-to-preclinical continuum by enabling hypothesis testing, quantitative readouts, and standardized analytics for vascular pressure endpoints.
- Discovery Biology: Supports hypothesis-driven interrogation of vascular mechanisms and pressure modulation.
- Screening: Delivers reproducible, quantitative pressure outputs for compound evaluation.
- Analytics: Provides subharmonic amplitude measurements and logistic curve-based optimization for robust data comparison.
- Translational Research: Bridges discovery and preclinical validation with disease-relevant pressure biomarkers.
- Enterprise Reuse: Establishes a reusable, noninvasive platform for pressure estimation across multiple disease models.
Operational & Enterprise Impact
- Scientific Value: Increases predictive confidence and reduces mechanistic ambiguity in vascular target validation.
- Operational Value: Standardizes pressure measurement workflows and enhances reproducibility.
- Strategic Value: Enables better go/no-go decisions and reduces late-stage biological risk.
- Portfolio Impact: Supports risk-adjusted prioritization and advancement of vascular and hepatic programs.
Implementation Considerations
- Requires expertise in ultrasound imaging and contrast agent handling.
- Needs access to subharmonic-capable ultrasound systems and analytical software.
- Demands cross-team standardization of imaging protocols and data analysis.
- May require adaptation for different anatomical sites or disease models.
- Diagnostic accuracy can be affected by anatomical or vascular variations in some subjects.
Biopharma FAQs
Why does null hypothesis testing matter for SHAPE-based target validation?
Null hypothesis testing using SHAPE-derived pressure measurements enables objective evaluation of intervention effects on vascular endpoints. This supports rigorous target validation and reduces the risk of false positives in early discovery. Quantitative outputs from SHAPE facilitate statistically robust decision-making for advancing candidates.
How does independent variable isolation fit SHAPE pressure estimation in discovery?
Isolating variables such as acoustic output and region of interest during SHAPE imaging ensures that pressure changes are attributable to specific interventions. This enhances mechanistic clarity and supports reliable hypothesis testing in the discovery pipeline. Controlled imaging parameters improve reproducibility across studies.
What do quantitative subharmonic amplitude measurements enable in R&D?
Quantitative subharmonic amplitude measurements provide real-time, reproducible pressure estimates for vascular endpoints. These outputs enable direct comparison of intervention effects and support data-driven advancement decisions. They also facilitate assay standardization and cross-study analytics.
Why are replication requirements critical for SHAPE cross-functional collaboration?
Replication of SHAPE imaging protocols and pressure measurements ensures data reliability across teams and sites. Standardized workflows enable consistent interpretation of results, supporting cross-functional collaboration in multi-site R&D programs. Reliable replication underpins portfolio-wide confidence in pressure-based endpoints.
What statistical analysis capabilities are required before SHAPE implementation?
Robust statistical analysis of SHAPE data requires curve fitting, inflection point determination, and quantitative comparison of pressure estimates. Teams must ensure analytical infrastructure supports these requirements to enable valid interpretation and decision-making. Proper analytics are essential for integrating SHAPE outputs into R&D workflows.
